Acadia Selected to Participate in Seelos Therapeutics Study

Acadia Healthcare announced September 14 that it has been selected by Seelos Therapeutics to participate in the registration-directed study of using intranasal racemic ketamine for the treatment of individuals who have major depressive disorder. The study aims to determine if the use of this medication can reduce or eliminate the presence of suicidal ideation in patients who are also receiving traditional therapeutic care. Select Acadia facilities that meet criteria for this clinical trial will participate in the study. 

Read More